These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24097868)

  • 1. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
    Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
    MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
    Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT
    Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
    Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
    Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
    Thomas M; Kienast Y; Scheuer W; Bähner M; Kaluza K; Gassner C; Herting F; Brinkmann U; Seeber S; Kavlie A; Welschof M; Ries S; Weidner KM; Regula JT; Klein C
    PLoS One; 2013; 8(2):e54923. PubMed ID: 23405099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
    Regula JT; Lundh von Leithner P; Foxton R; Barathi VA; Cheung CM; Bo Tun SB; Wey YS; Iwata D; Dostalek M; Moelleken J; Stubenrauch KG; Nogoceke E; Widmer G; Strassburger P; Koss MJ; Klein C; Shima DT; Hartmann G
    EMBO Mol Med; 2016 Nov; 8(11):1265-1288. PubMed ID: 27742718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
    Rad FH; Le Buanec H; Paturance S; Larcier P; Genne P; Ryffel B; Bensussan A; Bizzini B; Gallo RC; Zagury D; Uzan G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2837-42. PubMed ID: 17301234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
    Ghosh S; Maity P
    Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Waltenberger H; Hansbauer A; Koehler A; Heinrich J
    J Pharm Biomed Anal; 2015 Jan; 102():459-67. PubMed ID: 25459946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
    Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.
    Cao Y; Sonveaux P; Liu S; Zhao Y; Mi J; Clary BM; Li CY; Kontos CD; Dewhirst MW
    Cancer Res; 2007 Apr; 67(8):3835-44. PubMed ID: 17440098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.